Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780680 | 0.88 | KCNH2 (0.41) | MEN1KMT2APOLA1KCNH2 | |
| SCHEMBL6782326 | 0.87 | KCNH2 (0.38) | MEN1KMT2APOLA1KCNH2 | |
| SCHEMBL6787699 | 0.86 | KCNH2 (0.43) | MEN1KMT2APOLA1F2KCNH2 | |
| SCHEMBL6727073 | 0.74 | POLA1 (0.46) | MEN1KMT2APOLA1KCNH2 | |
| SCHEMBL6697177 | 0.74 | KCNH2 (0.47) | POLA1KCNH2 | |
| SCHEMBL6419485 | 0.74 | POLA1 (0.51) | MEN1KMT2APOLA1F2KCNH2 | |
| SCHEMBL6701225 | 0.73 | KCNH2 (0.42) | POLA1KCNH2 | |
| SCHEMBL6732670 | 0.68 | POLA1 (0.47) | MEN1KMT2APOLA1KCNH2 | |
| SCHEMBL7854710 | 0.68 | MAPT (0.52) | MEN1KMT2APOLA1KCNH2 | |
| SCHEMBL6735419 | 0.67 | KCNH2 (0.46) | MEN1KMT2APOLA1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6673793-B2 | N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY | PHARMACIA & UPJOHN CO. | 2004-01-06 | — | — | US | disclosed |
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | ZC3HAV1, RPL5, ZC3HAV1L | MEN1 2703/4885KMT2A 3221/4885POLA1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.